r/investing Apr 27, 05:25 PM
$500M into neurotechnology in two weeks. Here's what it actually means. Neurotech just had a hell of a fortnight. Here's where the money went:
Sergey Brin's Nexus NeuroTech Ventures folded into family office Bayshore Global Management, 15-company portfolio intact
Ground Effect Ventures launched immediately as its replacement in the BrainTech Alliance
Newfund closes €60M dedicated brain tech fund out of Paris
ARPA-H commits $139M for behavioural health through the EVIDENT initiative
Cala Health secures $50M growth capital for its FDA-cleared wearable tremor device
ONWARD Medical raises €40.6M, runway extended to Q1 2028
Nervonik closes oversubscribed $52.5M Series B for closed-loop peripheral nerve stimulation
Harvard neuroscientist Gabriel Kreiman leaves academia to raise $100M at $1B valuation for AI memory startup
Click Therapeutics and Boehringer Ingelheim announce Series D for digital therapeutic targeting schizophrenia
NightWare closes $1.4M to expand VA Pathfinder Pilot and first responder coverage
Jetstream Venture Fund secures positions in Surf Therapeutics and Hill Research
A few things stand out when you look at this together.
The Brin move isn't an exit, it's a consolidation. Pulling $200M of neurotech bets closer to the family office while the former fund team immediately launches a replacement suggests conviction, not retreat.
The capital is maturing. Most of these rounds are going into commercialisation-stage, FDA-cleared devices looking to scale. That's a different risk profile from the speculative early-stage rounds that dominated neurotech two or three years ago.
Dedicated neurotech investment vehicles are multiplying. Family offices, European early-stage funds, government-backed programmes. The sector is building its own financial architecture rather than relying on generalist medtech or biotech funds to show up.
Behavioural health is getting serious money. ARPA-H's $139M and the Click Therapeutics Series D both point to mental health moving from research priority to genuine commercial priority.
The wildcard is Kreiman. Memory is one of the least commercially developed areas in neurotech and one of the most interesting given the scale of Alzheimer's and cognitive decline globally. Worth watching.
Anyone investing in Neurotech?
submitted by /u/NeurotechNewsletter
[link] [comments]